Advanced search
Publication Cover
Expert Review of Obstetrics & Gynecology Volume 7, 2012 - Issue 6
Journal homepage
4
Views
1
CrossRef citations to date
0
Altmetric
Review

Management of refractory overactive bladder

Maude E Carmel Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH, USA. [email protected]
&
Howard B Goldman Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH, USA
Pages 605-613 | Published online: 10 Jan 2014

References

  • Abrams P, Cardozo L, Fall M et al.; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol. Urodyn. 21(2), 167–178 (2002).
  • Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87(9), 760–766 (2001).
  • Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 20(6), 327–336 (2003).
  • Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 68(Suppl. 2), 3–8 (2006).
  • Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst. Rev. 1, CD005654 (2010).
  • Chapple CR, Martinez-Garcia R, Selvaggi L et al.; The STAR Study Group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol. 48(3), 464–470 (2005).
  • Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur. Urol. 54(3), 543–562 (2008).
  • Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet. Gynecol. 112(6), 1311–1318 (2008).
  • Abrams PA, Birder L, Brubaker L et al. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Incontinence. Abrams PC, Khoury S, Wein A (Eds). Health Publication, MA, USA, 1767–1816 (2009).
  • Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J. Urol. 171(6 Pt 1), 2128–2137 (2004).
  • Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur. Urol. 49(4), 644–650 (2006).
  • Karsenty G, Denys P, Amarenco G et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur. Urol. 53(2), 275–287 (2008).
  • Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur. Urol. 49(3), 528–535 (2006).
  • Khan S, Kessler TM, Apostolidis A et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J. Urol. 181(4), 1773–1778 (2009).
  • Schmid DM, Sauermann P, Werner M et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J. Urol. 176(1), 177–185 (2006).
  • Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 96(6), 848–852 (2005).
  • Ghalayini IF, Al-Ghazo MA. Intradetrusorm injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol. Urodyn. 26, 531–536 (2007).
  • Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J. Urol. 174(3), 984–989 (2005).
  • Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J. Urol. 178(4 Pt 1), 1359–1363 (2007).
  • Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J. Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J. Urol. 177, 1011–1014 (2007).
  • Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT. Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can. J. Urol. 13(5), 3291–3295 (2006).
  • Manecksha RP, Cullen IM, Ahmad S et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur. Urol. 61(5), 928–935 (2012).
  • Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J. Urol. 177(6), 2231–2236 (2007).
  • Brubaker L, Richter HE, Visco A et al.; Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J. Urol. 180(1), 217–222 (2008).
  • Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J. Urol. 181(6), 2608–2615 (2009).
  • Dmochowski R, Chapple C, Nitti VW et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J. Urol. 184(6), 2416–2422 (2010).
  • Denys P, Le Normand L, Ghout I et al.; VESITOX study group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur. Urol. 61(3), 520–529 (2012).
  • Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol. Urodyn. 30(4), 556–562 (2011).
  • Makovey I, Davis T, Guralnick ML, O’Connor RC. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability. Neurourol. Urodyn. 30(8), 1538–1540 (2011).
  • Gousse AE, Kanagarajah P, Ayyathurai R, Handa P, Dabas N, Gomez CS. Repeat intradetrusor injections of onabotulinum toxin a for refractory idiopathic overactive bladder patients: a single-center experience. Female Pelvic Med. Reconstr. Surg. 17(5), 253–257 (2011).
  • Powell CR. Status of tibial nerve stimulation for overactive bladder. Curr. Bladder Dysfunct. Rep. 7, 59–65 (2012).
  • Peters KM, Carrico DJ, Perez-Marrero RA et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J. Urol. 183(4), 1438–1443 (2010).
  • Peters K, Carrico D, MacDiarmid S, Woolbridge L, Khan A. 30 month study results using posterior tibial nerve stimulation: long term efficacy outcomes. Presented at: The American Urological Association Annual Meeting. Atlanta, GA, USA, 19–23 May 2012.
  • Peters KM, Macdiarmid SA, Wooldridge LS et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J. Urol. 182(3), 1055–1061 (2009).
  • Peters K, Carrico D, Wooldridge L. Treatment interval frequency of percutaneous tibial nerve stimulation: 18-month results from the STEP study. Presented at: The International Continence Society. Glasgow, UK, 29 August–2 September 2011.
  • Siddiqui NY, Wu JM, Amundsen CL. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. Neurourol. Urodyn. 29(Suppl. 1), S18–S23 (2010).
  • Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE. Cost–effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int. 108(4), 558–564 (2011).
  • Everaert K, Kerckhaert W, Caluwaerts H et al. A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur. Urol. 45(5), 649–654 (2004).
  • Janknegt RA, Weil EH, Eerdmans PH. Improving neuromodulation technique for refractory voiding dysfunctions: two-stage implant. Urology 49(3), 358–362 (1997).
  • Borawski KM, Foster RT, Webster GD, Amundsen CL. Predicting implantation with a neuromodulator using two different test stimulation techniques: a prospective randomized study in urge incontinent women. Neurourol. Urodyn. 26(1), 14–18 (2007).
  • Schmidt RA, Jonas U, Oleson KA et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J. Urol. 162(2), 352–357 (1999).
  • Weil EH, Ruiz-Cerda JL, Eerdmans PH, Janknegt RA, Bemelmans BL, van Kerrebroeck PE. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur. Urol. 37, 161–171 (2000).
  • Hassouna MM, Siegel SW, Nÿeholt AA et al. Sacral neuromodulation in the treatment of urgency–frequency symptoms: a multicenter study on efficacy and safety. J. Urol. 163(6), 1849–1854 (2000).
  • Hijaz A, Vasavada SP, Daneshgari F, Frinjari H, Goldman H, Rackley R. Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience. Urology 68(3), 533–537 (2006).
  • Sutherland SE, Lavers A, Carlson A, Holtz C, Kesha J, Siegel SW. Sacral nerve stimulation for voiding dysfunction: one institution’s 11-year experience. Neurourol. Urodyn. 26(1), 19–28; discussion 36 (2007).
  • van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J. Urol. 178(5), 2029–2034 (2007).
  • Van Voskuilen AC, Oerlemans DJ, Weil EH, de Bie RA, van Kerrebroeck PE. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur. Urol. 49, 366–372 (2006).
  • Van Voskuilen AC, Oerlemans DJ, Weil EH, van den Hombergh U, van Kerrebroeck PE. Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int. 99, 107–110 (2007).
  • Cappellano F, Bertapelle P, Spinelli M et al.; Italian Group of Sacral Neuromodulation (GINS). Quality of life assessment in patients who undergo sacral neuromodulation implantation for urge incontinence: an additional tool for evaluating outcome. J. Urol. 166(6), 2277–2280 (2001).
  • Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology 66(4), 746–750 (2005).
  • Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J. Urol. 186(3), 954–959 (2011).
  • Guralnick ML, Benouni S, O’Connor RC, Edmiston C. Characteristics of infections in patients undergoing staged implantation for sacral nerve stimulation. Urology 69(6), 1073–1076 (2007).
  • Aboseif SR, Kim DH, Rieder JM et al. Sacral neuromodulation: cost considerations and clinical benefits. Urology 70(6), 1069–1073; discussion 1073 (2007).
  • Mundy AR, Stephenson TP. ‘Clam’ ileocystoplasty for the treatment of refractory urge incontinence. Br. J. Urol. 57(6), 641–646 (1985).
  • Sethia KK, Webb RJ, Neal DE. Urodynamic study of ileocystoplasty in the treatment of idiopathic detrusor instability. Br. J. Urol. 67(3), 286–290 (1991).
  • Hasan ST, Marshall C, Robson WA, Neal DE. Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. Br. J. Urol. 76(5), 551–557 (1995).
  • Blaivas JG, Weiss JP, Desai P, Flisser AJ, Stember DS, Stahl PJ. Long-term followup of augmentation enterocystoplasty and continent diversion in patients with benign disease. J. Urol. 173(5), 1631–1634 (2005).
  • Awad SA, Al-Zahrani HM, Gajewski JB, Bourque-Kehoe AA. Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. Br. J. Urol. 81(4), 569–573 (1998).
  • Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int. 88(6), 511–525 (2001).
  • Venn SN, Mundy AR. Long-term results of augmentation cystoplasty. Eur. Urol. 34(Suppl. 1), 40–42 (1998).
  • Reyblat P, Ginsberg DA. Augmentation enterocystoplasty in overactive bladder: is there still a role? Curr. Urol. Rep. 11(6), 432–439 (2010).
  • Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int. 109(9), 1280–1293 (2012).
  • Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N. The efficacy and safety of mirabegron in patients with overactive bladder syndrome – results from a North-American Phase III trial. Presented at: The 26th Annual European Association of Urology Annual Congress. Vienna, Austria, 18–22 March 2011.
  • Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3- adrenoceptor agonist solabegron for overactive bladder. Eur. Urol. doi:10.1016/j. eururo.2012.05.053 (2012) (In Press).
  • Andersson KE. Prospective pharmacologic therapies for the overactive bladder. Ther. Adv. Urol. 1(2), 71–83 (2009).
  • Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J. Urol. 176(6 Pt 1), 2535–2540; discussion 2540 (2006).
  • Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J. Urol. 184(2), 616–622 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.